ArticleFrontiers in neuroscience2026
Suppression of miR-195 attenuates oxygen-glucose deprivation/reperfusion-induced BBB destruction, possibly via targeting BCL2L2.
Article in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Actin polymerization drives endogenous MMP-9 upregulation and blood-brain barrier disruption in ischemic brain endothelial cells.Molecular and cellular biochemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: MicroRNAs (miRNAs) are highly expressed in the brain and represent promising therapeutic targets for the treatment of ischemic stroke. Previous studies have shown that microRNA-195 (miR-195) is associated with apoptosis and is significantly upregulated in the serum of patients with ischemic stroke. We aimed to confirm the role of miR-195 in brain microvascular endothelial cell (BMEC) apoptosis and blood-brain barrier (BBB) integrity. Materials and methods: bEnd.3 cells were exposed to oxygen-glucose deprivation/reperfusion (OGD/R). RT-qPCR was used to determine the relative expression of miRNA-195. Bioinformatics analysis using the TargetScan database predicted BCL2L2 as a potential target of miR-195. A BBB model was constructed by culturing bEnd.3 cells in the upper Transwell chambers. Transepithelial/transendothelial electrical resistance (TEER) and the fluorescein isothiocyanate (FITC)-dextran assay were used to assess BBB permeability. Immunofluorescence staining for caspase-3, TdT-mediated dUTP nick end labeling (TUNEL) staining, and flow cytometric analysis were used to measure bEnd.3 cell apoptosis. Tight junction proteins (TJPs) expression was determined using western blot analysis. Results: miR-195 expression was upregulated in the Conclusion: Our results suggest that the miR-195/BCL2L2 axis plays a critical role in the regulation of bEnd.3 cell apoptosis. Modulation of miR-195 may represent a novel therapeutic strategy for targeting BMEC apoptosis in ischemic stroke.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.